期刊
PHARMACEUTICS
卷 12, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics12060576
关键词
pancreatic cancer; targeted tumor therapy; homing peptide; antitumor peptide conjugates; daunomycin; oxime linkage
资金
- National Research, Development and Innovation Office [NKFIH K119552, NVKP_16-1-2016-0036]
- European Union [VEKOP-2.3.3-15-2017-00020]
- State of Hungary
- European Regional Development Fund
- Hungarian Ministry for Innovation and Technology
- MTA Premium Post-Doctorate Research Program of the Hungarian Academy of Sciences (HAS, MTA)
- 2019 Thematic Excellence Program [TUDFO/51757/2019-ITM]
The Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most aggressive and dangerous cancerous diseases, leading to a high rate of mortality. Therefore, the development of new, more efficient treatment approaches is necessary to cure this illness. Peptide-based drug targeting provides a new tool for this purpose. Previously, a hexapeptide Cys-Lys-Ala-Ala-Lys-Asn (CKAAKN) was applied efficiently as the homing device for drug-loaded nanostructures in PDAC cells. In this research, Cys was replaced by Ser in the sequence and this new SKAAKN targeting moiety was used in conjugates containing daunomycin (Dau). Five different structures were developed and tested. The results indicated that linear versions with one Dau were not effective on PANC-1 cells in vitro; however, branched conjugates with two Dau molecules showed significant antitumor activity. Differences in the antitumor effect of the conjugates could be explained with the different cellular uptake and lysosomal degradation. The most efficient conjugate wasDau=Aoa-GFLG-K(Dau=Aoa)SKAAKN-OH(conjugate4) that also showed significant tumor growth inhibition ons.c.implanted PANC-1 tumor-bearing mice with negligible side effects. Our novel results suggest that peptide-based drug delivery systems could be a promising tool for the treatment of pancreatic cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据